Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash, Abdul Rafeh
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. [electronic resource] - Journal for immunotherapy of cancer 01 2019 - 4 p. digital
Publication Type: Case Reports; Journal Article
2051-1426
10.1186/s40425-018-0475-y doi
Antibodies, Monoclonal, Humanized--adverse effects
Antineoplastic Agents, Immunological--adverse effects
Azetidines--adverse effects
Exanthema--chemically induced
Female
Humans
Immunotherapy--adverse effects
MAP Kinase Kinase Kinases--antagonists & inhibitors
Male
Melanoma--drug therapy
Middle Aged
Nivolumab--adverse effects
Piperidines--adverse effects
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Protein Kinase Inhibitors--adverse effects
Skin--drug effects
Skin Neoplasms--drug therapy
Vemurafenib--adverse effects
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. [electronic resource] - Journal for immunotherapy of cancer 01 2019 - 4 p. digital
Publication Type: Case Reports; Journal Article
2051-1426
10.1186/s40425-018-0475-y doi
Antibodies, Monoclonal, Humanized--adverse effects
Antineoplastic Agents, Immunological--adverse effects
Azetidines--adverse effects
Exanthema--chemically induced
Female
Humans
Immunotherapy--adverse effects
MAP Kinase Kinase Kinases--antagonists & inhibitors
Male
Melanoma--drug therapy
Middle Aged
Nivolumab--adverse effects
Piperidines--adverse effects
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Protein Kinase Inhibitors--adverse effects
Skin--drug effects
Skin Neoplasms--drug therapy
Vemurafenib--adverse effects